Tarek Hassan, MD
Retina Specialist · Royal Oak, MINPI 1154367902
Payments from drug & device makers
Across 256 payments — averaging $3129.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$348K
- Oculus Surgical Inc.$282K
- AbbVie$55K
- Novartis Pharma AG$44K
- Katalyst Surgical, LLC$21K
- Beaver-visitec International, Inc.$16K
- plus $36K from 19 others
Across 1 payment — averaging $1260.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 18 | $348,140 |
| Oculus Surgical Inc. | 24 | $281,736 |
| AbbVie(2 entities) | 74 | $54,729 |
| Novartis Pharma AG | 8 | $43,538 |
| Katalyst Surgical, LLC | 9 | $21,087 |
| Beaver-visitec International, Inc. | 4 | $16,023 |
| Alcon | 16 | $12,984 |
| Alimera Sciences, Inc. | 18 | $7,093 |
| Coherus Oncology, Inc. | 2 | $4,000 |
| Apellis Pharmaceuticals, Inc. | 6 | $3,197 |
| Alcon Research LLC | 2 | $2,400 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $1,931 |
| Eyepoint US, Inc. | 2 | $1,525 |
| Regeneron Healthcare Solutions, Inc. | 32 | $988 |
| Ocular Therapeutix, Inc. | 6 | $387 |
| Genentech USA, Inc. | 11 | $313 |
| ANI Pharmaceuticals, Inc. | 2 | $220 |
| Genentech, Inc. | 2 | $215 |
| Johnson & Johnson | 2 | $156 |
| Bausch & Lomb Americas Inc. | 1 | $152 |
| Iridex Corporation | 2 | $149 |
| Astellas Pharma US Inc | 5 | $144 |
| Notal Vision, Inc. | 1 | $75 |
| Biogen | 1 | $23 |
| Regeneron | 1 | $23 |
How this compares
$801,227 in reported general payments places this provider in the 95th percentile of 52 retina specialist providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other retina specialist in Royal Oak
- Jeremy WolfeRoyal Oak$3.6M
- Lisa FaiaRoyal Oak$657K
- Antonio CaponeRoyal Oak$179K
- Sandeep RandhawaRoyal Oak$98K
- Kimberly DrenserRoyal Oak$87K
- Michael TreseRoyal Oak$69K
- Adam WeinerRoyal Oak$31K
- Ramon LeeRoyal Oak$19K
- Jong ParkRoyal Oak$12K
- Tianyu LiuRoyal Oak$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.